Bessemer Group’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1K | Hold |
258
| – | – | ﹤0.01% | 2478 |
|
|
2026
Q1 | $1K | Sell |
258
-204
| -44% | -$1.06K | ﹤0.01% | 2448 |
|
|
2025
Q4 | $3K | Buy |
462
+258
| +126% | +$1.87K | ﹤0.01% | 2361 |
|
|
2025
Q3 | $1K | Buy |
+204
| New | +$1.21K | ﹤0.01% | 2429 |
|
|
2024
Q4 | – | Sell |
-2,550
| Closed | -$70K | – | 2603 |
|
|
2024
Q3 | $70K | Buy |
+2,550
| New | +$69K | ﹤0.01% | 1332 |
|
|
2024
Q1 | – | Sell |
-135
| Closed | -$3K | – | 2146 |
|
|
2023
Q4 | $3K | Buy |
+135
| New | +$2.33K | ﹤0.01% | 1942 |
|
|
2023
Q3 | – | Sell |
-68
| Closed | -$2K | – | 2272 |
|
|
2023
Q2 | $2K | Buy |
+68
| New | +$1.48K | ﹤0.01% | 2052 |
|
|
2022
Q3 | – | Sell |
-398
| Closed | -$7K | – | 2115 |
|
|
2022
Q2 | $7K | Hold |
398
| – | – | ﹤0.01% | 1452 |
|
|
2022
Q1 | $10K | Hold |
398
| – | – | ﹤0.01% | 1388 |
|
|
2021
Q4 | $11K | Hold |
398
| – | – | ﹤0.01% | 1400 |
|
|
2021
Q3 | $13K | Hold |
398
| – | – | ﹤0.01% | 1315 |
|
|
2021
Q2 | $12K | Hold |
398
| – | – | ﹤0.01% | 1315 |
|
|
2021
Q1 | $12K | Buy |
+398
| New | +$11.3K | ﹤0.01% | 1272 |
|
|
2018
Q4 | – | Sell |
-50
| Closed | -$2K | – | 2016 |
|
|
2018
Q3 | $2K | Buy |
+50
| New | +$2.22K | ﹤0.01% | 1766 |
|
|
2016
Q3 | – | Sell |
-202,035
| Closed | -$6.18M | – | 1857 |
|
|
2016
Q2 | $6.18M | Buy |
202,035
+69,390
| +52% | +$2.41M | 0.03% | 268 |
|
|
2016
Q1 | $4.96M | Buy |
+132,645
| New | +$5M | 0.03% | 291 |
|
|
2015
Q3 | – | Sell |
-33,217
| Closed | -$1.13M | – | 1694 |
|
|
2015
Q2 | $1.13M | Hold |
33,217
| – | – | 0.01% | 523 |
|
|
2015
Q1 | $1.18M | Buy |
33,217
+6,317
| +23% | +$226K | 0.01% | 502 |
|
|
2014
Q4 | $916K | Buy |
+26,900
| New | +$954K | ﹤0.01% | 490 |
|
|
2014
Q2 | – | Sell |
-3,200
| Closed | -$109K | – | 1451 |
|
|
2014
Q1 | $109K | Sell |
3,200
-296,800
| -99% | -$9.2M | ﹤0.01% | 721 |
|
|
2013
Q4 | $6.29M | Buy |
+300,000
| New | +$7.59M | 0.05% | 195 |
|
|
2013
Q3 | – | Sell |
-178,574
| Closed | -$4.8M | – | 1333 |
|
|
2013
Q2 | $4.8M | Buy |
+178,574
| New | +$5.18M | 0.04% | 209 |
|
Other funds holding MYGN
VPC
Bessemer Group's MYGN Position: Q2 2026 in Review
Bessemer Group held its Myriad Genetics (MYGN) position steady in Q2 2026 at 258 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2478.
Bessemer Group first reported a position in MYGN in Q2 2013 and has held it in 22 quarters since. The position peaked at $6.29M in Q4 2013. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- Bessemer Group held 258 shares of Myriad Genetics worth $1K as of Q2 2026.
- Bessemer Group left its Myriad Genetics share count unchanged in Q2 2026.
- Myriad Genetics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2478 holding.
- Bessemer Group first reported a position in Myriad Genetics in Q2 2013 and has held it in 22 quarters since.
- Bessemer Group's Myriad Genetics position peaked at $6.29M in Q4 2013.
- 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.